Finding recruiting trials…
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Live ClinicalTrials.gov status

Recruiting Psilocybin Clinical Trials

Find registry-listed psilocybin studies currently marked Recruiting, compare their conditions, phases, sponsors, and study locations, and confirm participation details in the authoritative registry record.

Registry status is not a guarantee of local availability or eligibility. Always verify the study record and contact the listed study team through ClinicalTrials.gov.

98recruiting trials
124registry-listed sites
16countries represented

Registry facts checkedAug 10, 2026 01:26 UTC

Current recruiting landscape

Where and what is recruiting now

Counts below are recomputed automatically from records whose exact ClinicalTrials.gov overall status is RECRUITING.

Leading countries

  1. United States60 trials
  2. Canada16 trials
  3. Israel4 trials
  4. Switzerland3 trials
  5. Brazil2 trials
  6. Denmark2 trials
  7. Netherlands2 trials
  8. Sweden2 trials

Common conditions

  1. Depression10
  2. Healthy6
  3. Major Depressive Disorder6
  4. Opioid Use Disorder6
  5. PTSD6
  6. Treatment Resistant Depression5
  7. Anxiety5
  8. Alcohol Use Disorder4

Trial phases

  1. Phase 255
  2. Phase 133
  3. Early Phase 111
  4. Phase 35
  5. Not applicable1
Interactive recruiting map

Explore recruiting study locations

The embedded map opens with the exact Recruiting filter applied. Use its country, condition, phase, intervention, and date controls to refine the current registry view.

Open full map
Server-rendered registry index

98 recruiting psilocybin trials

These factual summaries are available without JavaScript. Open the linked ClinicalTrials.gov record for current eligibility, contacts, and site-level availability.

RecruitingNCT06349083

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

NYU Langone Health

Conditions
Alcohol Use Disorder
Phase
Phase 2
Enrollment
200 estimated
Locations
NYU Langone Health, New York, New York, United States
Registry updated
2026-08-07
RecruitingNCT06455293

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Joshua Woolley, MD, PhD

Conditions
Parkinson Disease · Depression
Phase
Phase 2
Enrollment
60 estimated
Locations
University of California, San Francisco, San Francisco, California, United States
Registry updated
2026-08-07
RecruitingNCT06233344

An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy

University of Southern California

Conditions
Mental Health
Phase
Phase 2
Enrollment
40 estimated
Locations
Univeristy of Southern California Brain and Creativity Institute, Los Angeles, California, United States
Registry updated
2026-08-06
RecruitingNCT06001749

Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

Yvan Beaussant, MD, MSci

Conditions
Opioid-Related Disorders · Pain Management · Pain Management and Care · Advanced Cancer
Phase
Phase 2
Enrollment
15 estimated
Locations
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Registry updated
2026-08-05
RecruitingNCT07118332

Psilocybin as a Treatment for Chronic Pain in Smokers

Yale University

Conditions
Smokers With Chronic Pain
Phase
Early Phase 1
Enrollment
10 estimated
Locations
Department of Veterans Affairs, West Haven, Connecticut, United States
Registry updated
2026-08-03
RecruitingNCT07737054

Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder

Tel-Aviv Sourasky Medical Center

Conditions
Post-Traumatic Stress Disorder, PTSD
Phase
Early Phase 1
Enrollment
13 estimated
Locations
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Registry updated
2026-07-30
RecruitingNCT06512220

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Centre for Addiction and Mental Health

Conditions
Treatment Resistant Depression
Phase
Phase 2
Enrollment
12 estimated
Locations
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Registry updated
2026-07-30
RecruitingNCT06518720

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

Centre for Addiction and Mental Health

Conditions
Treatment Resistant Depression · Chronic Pain
Phase
Phase 2
Enrollment
16 estimated
Locations
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Registry updated
2026-07-30
RecruitingNCT06706232

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

The University of Texas Health Science Center, Houston

Conditions
Bipolar II Disorder · Depression, Bipolar · Suicidality
Phase
Phase 2
Enrollment
10 estimated
Locations
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Registry updated
2026-07-30
RecruitingNCT07211438

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Centre for Addiction and Mental Health

Conditions
Treatment-Resistant Depression
Phase
Phase 2
Enrollment
40 estimated
Locations
Toronto Western Hospital (University Health Network), Toronto, Ontario, Canada · Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Registry updated
2026-07-30
RecruitingNCT06200155

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

M.D. Anderson Cancer Center

Conditions
Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
Phase
Phase 2
Enrollment
30 estimated
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Registry updated
2026-07-29
RecruitingNCT06801041

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

M.D. Anderson Cancer Center

Conditions
Depression · Anxiety · Cancer
Phase
Phase 2
Enrollment
20 estimated
Locations
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Registry updated
2026-07-29
RecruitingNCT05866471

Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin

University of Wisconsin, Madison

Conditions
Healthy · Psychedelic Experiences · Vagus Nerve Stimulation
Phase
Phase 1
Enrollment
108 estimated
Locations
University of Wisconsin - Madison, Madison, Wisconsin, United States
Registry updated
2026-07-29
RecruitingNCT07732166

Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.

Pontifícia Universidade Católica do Rio de Janeiro

Conditions
Healthy Adults
Phase
Early Phase 1
Enrollment
100 estimated
Locations
Centro de Pesquisas Matteo Ricci, Rio de Janeiro, Rio de Janeiro, Brazil
Registry updated
2026-07-28
RecruitingNCT06355414

Psilocybin and Affective Function in Chronic Lower Back Pain Depression

Johns Hopkins University

Conditions
Chronic Low-back Pain · Depression
Phase
Phase 1
Enrollment
40 estimated
Locations
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Registry updated
2026-07-24
RecruitingNCT07347405

A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Francisco A Moreno

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
30 estimated
Locations
The Clinical and Translational Sciences Research Center, Tucson, Arizona, United States
Registry updated
2026-07-23
RecruitingNCT05301608

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Johns Hopkins University

Conditions
Healthy
Phase
Phase 1 · Phase 2
Enrollment
30 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-07-23
RecruitingNCT06820723

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

Ohio State University

Conditions
Depression · Anxiety · Major Depressive Disorder
Phase
Phase 2
Enrollment
40 estimated
Locations
The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
Registry updated
2026-07-23
RecruitingNCT07610135

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Johns Hopkins University

Conditions
Mood (Psychological Function) · Well Being · Mood · Healthy
Phase
Phase 1 · Phase 2
Enrollment
20 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-07-21
RecruitingNCT06814522

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]

University of California, San Diego

Conditions
Burnout · Burnout, Healthcare Workers
Phase
Phase 1 · Phase 2
Enrollment
10 estimated
Locations
UC San Diego, San Diego, California, United States
Registry updated
2026-07-21
RecruitingNCT07610369

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Yale University

Conditions
Depression · Parkinson's Disease (PD)
Phase
Phase 2
Enrollment
40 estimated
Locations
Yale University, New Haven, Connecticut, United States
Registry updated
2026-07-20
RecruitingNCT06067737

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

Johns Hopkins University

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
90 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-07-17
RecruitingNCT06247839

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Sharmin Ghaznavi

Conditions
Major Depressive Disorder
Phase
Phase 3
Enrollment
20 estimated
Locations
Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
Registry updated
2026-07-17
RecruitingNCT07703722

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

Khyber Medical University Peshawar

Conditions
Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Phase
Phase 3
Enrollment
60 estimated
Locations
Institute of Health Science, Khyber Medical University, Islamabad, Capital, Pakistan · Hayatabad Medical Complex Peshawar, Peshawar, KPK, Pakistan · Khyber Medical University, Peshawar, KPK, Pakistan
Registry updated
2026-07-14
RecruitingNCT06464367

Mechanistic Studies of Psilocybin in Headache Disorders

Yale University

Conditions
Migraine
Phase
Early Phase 1
Enrollment
50 estimated
Locations
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Registry updated
2026-07-13
RecruitingNCT07063862

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

Bruyère Health Research Institute.

Conditions
Psychological Distress
Phase
Phase 3
Enrollment
120 estimated
Locations
William Osler Health System, Brampton, Ontario, Canada · Providence Care Hospital, Kingston, Ontario, Canada · St. Joseph's Healthcare, London, Ontario, Canada · +4 more
Registry updated
2026-07-10
RecruitingNCT05265546

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

University of California, Berkeley

Conditions
Perception Disorders
Phase
Phase 1
Enrollment
80 estimated
Locations
University of California, Berkeley, Berkeley, California, United States
Registry updated
2026-07-10
RecruitingNCT06810310

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

University of Pennsylvania

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
24 estimated
Locations
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Registry updated
2026-07-09
RecruitingNCT04161066

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation

University of Wisconsin, Madison

Conditions
Opioid Use Disorder
Phase
Phase 1
Enrollment
10 estimated
Locations
University of Wisconsin, Madison, Wisconsin, United States
Registry updated
2026-07-07
RecruitingNCT06160284

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Yale University

Conditions
Opioid Use Disorder
Phase
Phase 1
Enrollment
12 estimated
Locations
Yale University, New Haven, Connecticut, United States
Registry updated
2026-07-07
RecruitingNCT07516405

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

University of Colorado, Denver

Conditions
Healthy Volunteer · Older Adults (65-85 Years)
Phase
Phase 1
Enrollment
40 estimated
Locations
University of California San Francisco (UCSF) Department of Neurology, San Francisco, California, United States · University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States · Emory University Brain Health Center, Atlanta, Georgia, United States · +3 more
Registry updated
2026-07-06
RecruitingNCT07638553

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

Centre Hospitalier Universitaire de Nīmes

Conditions
Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
Phase
Phase 3
Enrollment
172 estimated
Locations
Centre Hospitalier de la Côte Basque, Bayonne, France · CHU Besançon, Besançon, France · CHU de Bordeaux, Bordeaux, France · +5 more
Registry updated
2026-07-01
RecruitingNCT06902974

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

Sunstone Medical

Conditions
Post Traumatic Stress Disorder · PTSD
Phase
Phase 2
Enrollment
70 estimated
Locations
Sunstone Medical, PC, Rockville, Maryland, United States
Registry updated
2026-07-01
RecruitingNCT05452772

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Johns Hopkins University

Conditions
Tobacco Use Disorder
Phase
Phase 2
Enrollment
66 estimated
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States · Johns Hopkins University School of Medicine, Baltimore, Maryland, United States · New York University, New York, New York, United States
Registry updated
2026-06-29
RecruitingNCT06386003

Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial

Unity Health Toronto

Conditions
Post Traumatic Stress Disorder · PTSD · Chronic PTSD
Phase
Phase 2
Enrollment
15 estimated
Locations
St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
Registry updated
2026-06-26
RecruitingNCT07104916

A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)

Anthony P King

Conditions
Post Traumatic Stress Disorder · Depression - Major Depressive Disorder
Phase
Phase 2
Enrollment
30 estimated
Locations
The Ohio State University Medical Center, Columbus, Ohio, United States
Registry updated
2026-06-25
RecruitingNCT07565493

Psilocybin Administration With 5-HT1a Blockade

Johns Hopkins University

Conditions
Psychedelic Effects in Healthy Volunteers
Phase
Early Phase 1
Enrollment
18 estimated
Locations
Center for Psychedelics and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-06-25
RecruitingNCT07048743

Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial

University Health Network, Toronto

Conditions
Caregiver Distress
Phase
Phase 2
Enrollment
15 estimated
Locations
Toronto General Hospital, Toronto, Ontario, Canada
Registry updated
2026-06-23
RecruitingNCT06724289

Psilocybin-Assisted Therapy for Prolonged Grief

University of Virginia

Conditions
Prolonged Grief Disorder
Phase
Early Phase 1
Enrollment
12 estimated
Locations
University of Virginia, Charlottesville, Virginia, United States
Registry updated
2026-06-23
RecruitingNCT07386730

A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease

Jennifer Mitchell

Conditions
Anhedonia in Healthy Volunteers · Older Adults (50-90 Years)
Phase
Phase 1
Enrollment
80 estimated
Locations
University of California San Francisco, Sandler Neuroscience Building, San Francisco, California, United States
Registry updated
2026-06-08
RecruitingNCT06626139

2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers

Robin Carhart-Harris, PhD, MA

Conditions
Healthy Participants With Lower-than-average Mental Well-being
Phase
Phase 2
Enrollment
120 estimated
Locations
UCSF Mission Bay, San Francisco, California, United States
Registry updated
2026-06-04
RecruitingNCT06768944

The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults

University of Calgary

Conditions
Investigating the Importance of the Subjective Psychedelic Experience
Phase
Phase 2
Enrollment
128 estimated
Locations
University of Calgary, Calgary, Alberta, Canada
Registry updated
2026-06-02
RecruitingNCT07506395

Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

University of New Mexico

Conditions
PTSD
Phase
Phase 1
Enrollment
36 estimated
Locations
Interdisciplinary Substance Use and Brain Injury (ISUBI), Albuquerque, New Mexico, United States
Registry updated
2026-05-22
RecruitingNCT07216404

Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)

Alan Davis

Conditions
Lung Non-Small Cell Carcinoma · Unipolar Depression
Phase
Phase 2
Enrollment
10 estimated
Locations
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Registry updated
2026-05-14
RecruitingNCT06782724

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

University Medical Center Groningen

Conditions
COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD)
Phase
Phase 2
Enrollment
108 estimated
Locations
National Institute of Mental Health, Prague, Czechia · Bispebjerg Hospital, Copenhagen, Denmark · University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands · +1 more
Registry updated
2026-05-08
RecruitingNCT07251491

Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury

James J. Peters Veterans Affairs Medical Center

Conditions
Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran
Phase
Phase 1 · Phase 2
Enrollment
30 estimated
Locations
James J. Peters Department of Veterans Affairs Medical Center, The Bronx, New York, United States
Registry updated
2026-05-04
RecruitingNCT05883540

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

University Hospital, Basel, Switzerland

Conditions
Palliative Care · Pain · Anxiety · Depression
Phase
Phase 2
Enrollment
60 estimated
Locations
University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland · University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland · Spital Uster AG, Division of Internal Medicine, Uster, Switzerland · +1 more
Registry updated
2026-04-29
RecruitingNCT06430541

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission

University of Colorado, Denver

Conditions
Breast Cancer · Ovarian Cancer
Phase
Phase 1
Enrollment
20 estimated
Locations
Outpatient CTRC, Aurora, Colorado, United States · University of Colorado Cancer Center, Aurora, Colorado, United States
Registry updated
2026-04-21
RecruitingNCT06319378

CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial

Section for Affective Disorders; Northern Stockholm Psychiatry

Conditions
MDD
Phase
Phase 2
Enrollment
100 estimated
Locations
region Västra Götaland, Gothenburg, Göteborg, Sweden · Norra Stockholms Psykiatri, Stockholm, Stockholm County, Sweden · Psykiatriska Kliniken, Akademiska Sjukhuset, Uppsala, Uppsala County, Sweden · +1 more
Registry updated
2026-04-13
RecruitingNCT06692192

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

University of Wisconsin, Madison

Conditions
Psilocybin
Phase
Phase 1
Enrollment
60 estimated
Locations
UW School of Medicine and Public Health, Madison, Wisconsin, United States
Registry updated
2026-04-03
RecruitingNCT06072898

Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

Sunnybrook Health Sciences Centre

Conditions
Depressive Disorder · Major Depressive Disorder
Phase
Phase 2
Enrollment
50 estimated
Locations
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Registry updated
2026-03-30
RecruitingNCT06898606

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

Federal University of Latin American Integration

Conditions
Depressive Disorder
Phase
Phase 1 · Phase 2
Enrollment
24 estimated
Locations
Federal University of Latin American Integration, Foz do Iguaçu, Paraná, Brazil
Registry updated
2026-03-27
RecruitingNCT07490353

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial

Medical University of Vienna

Conditions
Depression - Major Depressive Disorder · Anhedonia
Phase
Phase 1
Enrollment
85 estimated
Locations
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Vienna, State of Vienna, Austria
Registry updated
2026-03-24
RecruitingNCT06660381

Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder

Johns Hopkins University

Conditions
Cannabis Use Disorder
Phase
Phase 1
Enrollment
12 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-03-18
RecruitingNCT06818994

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study

Gustavo Vazquez

Conditions
Demoralization · Safety
Phase
Phase 1
Enrollment
15 estimated
Locations
Queen's University, Kingston, Ontario, Canada
Registry updated
2026-03-18
RecruitingNCT04123314

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

Johns Hopkins University

Conditions
Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
Phase
Early Phase 1
Enrollment
20 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-03-16
RecruitingNCT05068791

Psilocybin-facilitated Treatment for Chronic Pain

University of Alabama at Birmingham

Conditions
Fibromyalgia, Primary
Phase
Early Phase 1
Enrollment
30 estimated
Locations
UAB Beacon Tower, Birmingham, Alabama, United States
Registry updated
2026-03-11
RecruitingNCT06442423

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

Yale University

Conditions
Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
Phase
Phase 1
Enrollment
50 estimated
Locations
Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
Registry updated
2026-03-11
RecruitingNCT07169747

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults

Region Skane

Conditions
Anorexia Nervosa
Phase
Phase 2
Enrollment
40 estimated
Locations
Psykiatrikliniken, Baravägen 1, Lund, Sweden
Registry updated
2026-03-06
RecruitingNCT07072728

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

Psyence Australia Pty Ltd

Conditions
Adjustment Disorder · Adjustment Disorder With Anxious Mood · Cancer · Cancer Cachexia
Phase
Phase 2
Enrollment
87 estimated
Locations
Mind Medicine Australia Clinic, Abbotsford, Victoria, Australia · Paratus Clinical Research Melbourne, Northcote, Victoria, Australia · Empax Centre, Leederville, Western Australia, Australia
Registry updated
2026-03-03
RecruitingNCT06399263

Study of Psilocybin for Anorexia in Young Adults

Marissa Raymond-Flesch, MD, MPH

Conditions
Anorexia Nervosa
Phase
Phase 2
Enrollment
40 estimated
Locations
University of California, San Francisco, San Francisco, California, United States
Registry updated
2026-03-03
RecruitingNCT06450210

Safety for Home Administration of Microdose Psilocybin Use

Johns Hopkins University

Conditions
Psychedelic Experiences
Phase
Phase 1
Enrollment
20 estimated
Locations
5510 Nathan Shock Drive, Baltimore, Maryland, United States
Registry updated
2026-02-23
RecruitingNCT06772753

Investigation of Psychedelic Effects in Psychoactive Substances

Johns Hopkins University

Conditions
Psychedelic Effects in Healthy Volunteers
Phase
Phase 1
Enrollment
50 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-02-23
RecruitingNCT07053917

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

Johns Hopkins University

Conditions
Stroke · Chronic Stroke · Intracerebral Haemorrhage · Intracerebral Haemorrhage (ICH)
Phase
Phase 1
Enrollment
20 estimated
Locations
Johns Hopkins, Baltimore, Maryland, United States
Registry updated
2026-02-13
RecruitingNCT07281352

Psilocybin-Assisted Cognitive Behavioral Therapy for Depression

University of California, Los Angeles

Conditions
Major Depressive Diorder
Phase
Phase 1 · Phase 2
Enrollment
50 estimated
Locations
UCLA Semel Institute, Los Angeles, California, United States
Registry updated
2026-02-12
RecruitingNCT07079930

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

Hadassah Medical Organization

Conditions
Healthy Volunteers
Phase
Phase 1
Enrollment
10 estimated
Locations
Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel
Registry updated
2026-02-05
RecruitingNCT06796062

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

NYU Langone Health

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
480 estimated
Locations
Duke City Recovery Toolbox, Albuquerque, New Mexico, United States · University of New Mexico, Albuquerque, New Mexico, United States · StartCare, Brooklyn, New York, United States · +2 more
Registry updated
2026-01-23
RecruitingNCT06888128

The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

Baylor College of Medicine

Conditions
PTSD
Phase
Phase 2
Enrollment
15 estimated
Locations
Baylor College of Medicine, Houston, Texas, United States
Registry updated
2026-01-22
RecruitingNCT06656702

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Johns Hopkins University

Conditions
Amyotrophic Lateral Sclerosis
Phase
Early Phase 1
Enrollment
24 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2026-01-12
RecruitingNCT06615908

A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial

University of Calgary

Conditions
Persisting Symptoms After Concussion
Phase
Phase 1
Enrollment
40 estimated
Locations
University of Calgary, Calgary, Alberta, Canada
Registry updated
2025-12-30
RecruitingNCT06798636

Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study

Imperial College London

Conditions
Self Harm
Phase
Early Phase 1
Enrollment
30 estimated
Locations
Imperial College London, London, United Kingdom
Registry updated
2025-12-05
RecruitingNCT05585229

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study

University of British Columbia

Conditions
Opioid Dependence · Chronic Pain
Phase
Phase 2
Enrollment
10 estimated
Locations
University of British Columbia - Okanagan Campus, Kelowna, British Columbia, Canada
Registry updated
2025-12-04
RecruitingNCT05398484

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer

NYU Langone Health

Conditions
Advanced Cancer
Phase
Phase 2 · Phase 3
Enrollment
200 estimated
Locations
University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado, United States · NYU Langone Health, New York, New York, United States
Registry updated
2025-12-04
RecruitingNCT06405607

Psilocybin vs Ketamine for Alcohol Use Disorder

University of Iowa

Conditions
Alcohol Use Disorder · Alcohol Dependence · Alcohol Abuse
Phase
Phase 2
Enrollment
80 estimated
Locations
University of Iowa Health Care, Iowa City, Iowa, United States
Registry updated
2025-11-28
RecruitingNCT06815653

Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.

University College, London

Conditions
Healthy
Phase
Phase 1
Enrollment
40 estimated
Locations
University College London, London, United Kingdom
Registry updated
2025-11-26
RecruitingNCT06132178

Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

University of Texas at Austin

Conditions
Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression
Phase
Phase 2
Enrollment
100 estimated
Locations
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
Registry updated
2025-11-26
RecruitingNCT05403086

Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life

Charles S. Grob, M.D.

Conditions
Demoralization
Phase
Phase 2
Enrollment
100 estimated
Locations
Marin Cancer Care, Greenbrae, California, United States · University of California, Los Angeles, Los Angeles, California, United States · University of San Francisco, San Francisco, California, United States · +2 more
Registry updated
2025-11-25
RecruitingNCT07183748

A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression

Beersheva Mental Health Center

Conditions
Treatment Resistant Depression
Phase
Phase 2
Enrollment
20 estimated
Locations
Mental Health Center Beer Sheva, Beersheba, Israel
Registry updated
2025-11-19
RecruitingNCT04882839

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.

Beersheva Mental Health Center

Conditions
Obsessive-compulsive Disorder
Phase
Phase 2
Enrollment
15 estimated
Locations
Beer Sheva Mental Health Center, Beersheba, Israel
Registry updated
2025-11-19
RecruitingNCT06786325

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

Anna Rose Childress, Ph.D.

Conditions
Opioid Use Disorder
Phase
Phase 2
Enrollment
36 estimated
Locations
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Registry updated
2025-10-29
RecruitingNCT06367738

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

University of California, Berkeley

Conditions
Aging
Phase
Phase 1
Enrollment
40 estimated
Locations
University of California, Berkeley, Berkeley, California, United States
Registry updated
2025-10-21
RecruitingNCT06899594

A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine

Kevin Murnane

Conditions
Methamphetamine Use Disorder
Phase
Early Phase 1
Enrollment
20 estimated
Locations
LSU Health Shreveport, Shreveport, Louisiana, United States
Registry updated
2025-10-07
RecruitingNCT06989957

Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)

Johns Hopkins University

Conditions
Posttraumatic Stress Disorder
Phase
Phase 1
Enrollment
40 estimated
Locations
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Registry updated
2025-10-01
RecruitingNCT06368492

The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.

Maastricht University

Conditions
Fibromyalgia
Phase
Not applicable
Enrollment
35 estimated
Locations
Maastricht University, Maastricht, Limburg, Netherlands · Leiden University Medical Center, Leiden, South Holland, Netherlands
Registry updated
2025-09-15
RecruitingNCT06899165

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

Rachel Yehuda

Conditions
Psychological Stress · Depression · Anxiety
Phase
Phase 2
Enrollment
100 estimated
Locations
The Parsons Research Center for Psychedelic Healing, New York, New York, United States
Registry updated
2025-09-08
RecruitingNCT06853912

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

Nathan Brashares Sackett

Conditions
Alcohol Use Disorder (AUD) · PTSD
Phase
Phase 2
Enrollment
40 estimated
Locations
University of Washington Center for Novel Therapeutics in Addiction Psychiatry, Seattle, Washington, United States
Registry updated
2025-08-28
RecruitingNCT06796361

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

University Hospital, Basel, Switzerland

Conditions
Healthy
Phase
Phase 1
Enrollment
16 estimated
Locations
Clinical Trial Unit, Basel, Canton of Basel-City, Switzerland
Registry updated
2025-05-28
RecruitingNCT06512194

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

Charles Raison

Conditions
Depression
Phase
Phase 2
Enrollment
141 estimated
Locations
Vail Health Behavioral Health, Edwards, Colorado, United States
Registry updated
2025-05-23
RecruitingNCT06592833

Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

Icahn School of Medicine at Mount Sinai

Conditions
Major Depressive Disorder
Phase
Phase 2
Enrollment
60 estimated
Locations
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York, United States
Registry updated
2025-05-14
RecruitingNCT06969170

A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

Queen's University

Conditions
Generalized Anxiety Disorder (GAD)
Phase
Phase 2
Enrollment
50 estimated
Locations
Kingston General Health Research Institute, Kingston, Ontario, Canada
Registry updated
2025-05-13
RecruitingNCT06731335

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

Unity Health Toronto

Conditions
Chronic Neuropathic Pain · Pain Management
Phase
Phase 2
Enrollment
30 estimated
Locations
St. Michael's Hospital. Unity Health Toronto, Toronto, Ontario, Canada
Registry updated
2025-03-30
RecruitingNCT06899334

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)

University Hospital, Basel, Switzerland

Conditions
Healthy
Phase
Phase 1
Enrollment
24 estimated
Locations
University Hospital, Basel, Switzerland
Registry updated
2025-03-27
RecruitingNCT06225232

An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study

McMaster University

Conditions
Cannabis Use Disorder, Moderate · Cannabis Use Disorder, Severe
Phase
Phase 2
Enrollment
16 estimated
Locations
MacAnxiety Research Centre, Hamilton, Ontario, Canada
Registry updated
2025-03-19
RecruitingNCT03289949

The Neurobiological Effect of 5-HT2AR Modulation

Gitte Moos Knudsen

Conditions
Basic Science
Phase
Phase 1
Enrollment
200 estimated
Locations
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
Registry updated
2024-12-16
RecruitingNCT06506019

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study

University Health Network, Toronto

Conditions
Bipolar Depression
Phase
Phase 1
Enrollment
30 estimated
Locations
Toronto Western Hospital - University Health Network, Toronto, Ontario, Canada
Registry updated
2024-10-18
RecruitingNCT06378229

Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus

University Hospital, Ghent

Conditions
Treatment Resistant Depression
Phase
Phase 2
Enrollment
100 estimated
Locations
Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium
Registry updated
2024-09-19
RecruitingNCT06160232

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms

Brugmann University Hospital

Conditions
Severe Alcohol Use Disorder
Phase
Phase 2
Enrollment
62 estimated
Locations
Brugmann University Hospital, Brussels, Belgium
Registry updated
2024-08-07
RecruitingNCT05995769

Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial

University of Calgary

Conditions
Alcohol Use Disorder · Alcoholism
Phase
Phase 2
Enrollment
128 estimated
Locations
University of Calgary, Calgary, Alberta, Canada
Registry updated
2024-05-07
Provenance and interpretation

What “Recruiting” means here

Exact status: this page includes only records whose latest indexed ClinicalTrials.gov overall status is RECRUITING. “Not yet recruiting,” “enrolling by invitation,” and “active, not recruiting” are excluded.

Automatic updates: the list, counts, facets, and map are regenerated from the tracker after scheduled ClinicalTrials.gov refreshes. Registry facts can lag local changes, so the source record remains authoritative.

Rights-safe scope: titles, identifiers, sponsors, design facts, dates, interventions, conditions, and mapped sites are shown. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.

Editorial responsibility: authorship, collection rules, corrections, and scientific limitations are documented in the editorial policy and research methodology.

Related research views

Continue with curated, automatically updated trial collections built from the same source-preserving registry data.